Potassium citrate (also known as tripotassium citrate) is a potassium salt of citric acid. It is a white, hygroscopic crystalline powder. It is odorless with a saline taste. It contains 38.3% potassium by mass. In the monohydrate form it is highly hygroscopic and deliquescent. Potassium citrate is used to treat a kidney stone condition called renal tubular acidosis. Potassium Citrate is indicated also for the management of Hypocitraturic calcium oxalate nephrolithiasis.
Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -
Potassium Citrate
Drug Overview
What is Potassium Citrate?
To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).
Request Your Assessment
Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.
View Inquiry List →Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
Regulatory Framework
Assessment Methodology
Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.
EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)
Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.
PIC/S – Shared Facilities and Contamination Control Guidance
Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.
ICH Q9 – Quality Risk Management
Provides a structured methodology for risk identification, assessment, control, communication, and review.
ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)
Applied for compounds with potential mutagenic or genotoxic concerns.
Risk-Based Toxicological Assessment
Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.
Weight-of-Evidence (WoE) Approach
Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.
How We Work
Report Preparation Process
Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.
Comprehensive Data Review
Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.
Scientific Evaluation
Identification of critical endpoints and selection of appropriate exposure limits.
PDE / HBEL Derivation
Transparent and scientifically justified calculations aligned with global toxicological principles.
Ex-Agency Expert Review (Our Differentiator)
Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.
Final Report Delivery
Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).
Ex-Agency Advantage
Why Masuu Global?
Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.
Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.
Inspection-ready reports — scientifically defensible and audit-prepared from day one.
Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).
Practical implementation recommendations that translate science into actionable contamination control.
Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.
Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.
Ready to request your assessment?
Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.
Frequently Asked Questions
Potassium Citrate is a pharmaceutical substance or chemical compound identified by this name. Its pharmacological properties and the available substance-specific evidence may be relevant when evaluating occupational exposure and potential product carryover. A formal assessment should distinguish established information from assumptions and document the rationale for any recommended exposure limits or control measures.
A toxicological assessment characterizes the potential health hazards of (2R,4S)-2-Ethyl-6-(Trifluoromethyl)-1,2,3,4-Tetrahydroquinoline-4-Amine using the available data. It supports scientifically justified exposure limits, helps manufacturers choose proportionate handling and containment measures, and gives a documented basis for protecting workers and preventing cross-contamination in shared facilities.
An occupational exposure band for Potassium Citrate is a hazard-management category assigned under a defined banding framework, often to guide containment when quantitative data are limited. It does not automatically replace a substance-specific OEL. Where an OEL is available, the relationship between the band and the limit should be explained, and workplace controls should reflect the evidence and actual process conditions.
The assessment for Potassium Citrate should be reconsidered when meaningful new toxicological data become available, the substance’s use or manufacturing process changes, exposure conditions differ, or relevant guidance is updated. Review may also be appropriate when new information changes the understanding of a critical effect. The review should document the trigger, evidence considered, and whether existing limits and controls remain suitable.
The physical form in which Potassium Citrate is handled, such as a powder, granulated material, or solution, can influence how exposure may occur during routine operations. The assessment should consider the actual process, opportunities for dust, droplets, or aerosols, and the effectiveness of containment and work practices. Physical form does not independently determine toxicity, but it can affect exposure control decisions.
Not necessarily. A PDE or ADE is derived for a defined route of exposure, often oral for carryover into the next product. Extrapolating to inhalation or dermal exposure needs scientific justification, so the report should state the route, scope, and assumptions behind the value.
An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.
For Potassium Citrate, therapeutic dose information may provide context when it is relevant and reliable, but it is not automatically a suitable basis for a PDE, ADE, or OEL. The assessment must evaluate toxicological endpoints, dose-response evidence, route, and intended application. Any use of clinical or pharmacological information should be justified and considered alongside the full evidence package.
Where relevant to Potassium Citrate, available genotoxicity information should be reviewed as part of the overall assessment. If the substance falls within the scope of ICH M7, its principles may inform the evaluation of mutagenic impurities or compounds, as applicable. The approach depends on the substance’s role and evidence; no mutagenic classification should be assumed without adequate supporting data.
A toxicological assessment of Potassium Citrate organizes the available evidence about potential health hazards and uncertainty. Its conclusions can support scientifically justified exposure limits and proportionate controls for manufacturing, sampling, transfer, and cleaning. The assessment should distinguish established findings from assumptions and identify data gaps that may affect confidence in the recommendations.
Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.
Use the Request Your Assessment option on this page and add (2R,4S)-2-Ethyl-6-(Trifluoromethyl)-1,2,3,4-Tetrahydroquinoline-4-Amine to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.
